Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lofepramine is a tricyclic antidepressant (TCA) used primarily for the treatment of depression. It is structurally related to imipramine and is extensively metabolized to desipramine, which may contribute to its pharmacological effects[5][8]. Lofepramine acts mainly as a strong inhibitor of norepinephrine reuptake and as a moderate inhibitor of serotonin reuptake in the central nervous system[3][6][8]. It also exhibits weak-to-intermediate antagonism at muscarinic acetylcholine receptors, resulting in fewer anticholinergic side effects compared to some other TCAs[3][5]. Its therapeutic efficacy is considered comparable to other tricyclic antidepressants such as imipramine and amitriptyline. Lofepramine has been noted for a more favorable cardiac safety profile than many other TCAs and is licensed for use in the United Kingdom for unipolar depression[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lofepramine.